Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May 30;150(5):285-297.
doi: 10.1177/1715163517710958. eCollection 2017 Sep-Oct.

Guidelines for the management of atopic dermatitis (eczema) for pharmacists

Ian T Y Wong  1 , Ross T Tsuyuki  1 , Amanda Cresswell-Melville  1 , Philip Doiron  1 , Aaron M Drucker  1
Affiliations

Guidelines for the management of atopic dermatitis (eczema) for pharmacists

Ian T Y Wong et al. Can Pharm J (Ott). .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests:A. Cresswell-Melville is an employee of the Eczema Society of Canada (ESC), a registered Canadian charity, and has no conflict of interest or funding disclosure related to this publication. The Eczema Society of Canada receives funding from private citizen donations and foundations and funds, as well as from corporate partners, including Actelion Pharmaceuticals Ltd, Astellas Pharma, Beiersdorf Canada, Galderma Canada, Glaxo SmithKline Canada, Johnson & Johnson Inc., L’Oreal Canada Inc., Pediapharm Inc., Pierre Fabre Dermo-Cosmétique Canada Inc., Sanofi Canada, Skin Fix Inc., Valeant Canada and Wellspring Pharmaceuticals. A. M. Drucker is an investigator for Sanofi and Regeneron and a consultant for Sanofi. Dr. Drucker has received honoraria from Astellas Canada, Prime Inc. and Spire Learning.

Figures

Figure 1
Figure 1
Algorithm summary of atopic dermatitis management PRN, as needed; QoL, quality of life; TCS, topical corticosteroids; TCI, topical calcineurin inhibitors; systemic agents: glucocorticoid, cyclosporine, methotrexate, azathioprine, or mycophenolate mofetil.
See this image and copyright information in PMC

References

    1. Weidinger S, Novak N. Atopic dermatitis. Lancet Lond Engl 2016;387(10023):1109-22. - PubMed
    1. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI; ISAAC Phase Three Study Group. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol 2009;124(6):1251-8.e23. - PubMed
    1. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol 2013;132(5):1132-8. - PubMed
    1. Lee JH, Son SW, Cho SH. A comprehensive review of the treatment of atopic eczema. Allergy Asthma Immunol Res 2016;8(3):181-90. - PMC - PubMed
    1. Hanifin JM, Reed ML; Eczema Prevalence and Impact Working Group. A population-based survey of eczema prevalence in the United States. Dermat Contact Atopic Occup Drug 2007;18(2):82-91. - PubMed